(2013)13:436.doi:10.1186/1471-2407-13-436 25. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. (2008) 26:677–704. doi:10.1146/annurev.immunol.26.021607.090331 26. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD -L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. (2012) 24:207–12.doi:10.1016/j.coi.2011.12.009 27. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encod ing an ITIM motif-carrying immunoreceptor. Immunity. (1999) 11:141–51. doi:10.1016/S1074-7613(00)80089-8 28. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. (2009) 206:3015–29. doi:10.1084/jem.20090847 29. Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practic e Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2017) 28(Suppl_4):iv119–42.doi:10.1093/annonc/mdx225 30. Torphy RJ, Zhu Y, Schulick RD. Immunotherapy for pancreatic cancer : barriers and breakthroughs. Ann Gastroenterol Surg. (2018) 2:274–81. doi:10.1002/ags3.12176 31. Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, et al. Evaluating mismatch repair deﬁciency in pancreatic adenocarc inoma: challenges and recommendations. Clin Cancer Res. (2018) 24:1326–36. doi:10.1158/1078-0432.CCR-17-3099 32. Thind K, Padrnos LJ, Ramanathan RK, Borad MJ. Immunotherapy in pancreatic cancer treatment: a new frontier. Therap Adv Gastroenterol. (2017)10:168–94.doi:10.1177/1756283X16667909 33.